St. Jude Medical Inc. (NYSE:STJ) concluded its tender offer AGA Medical Holdings Inc. (NASDAQ:AGAM) and expects to close its $1.03 billion acquisition of the rival cardiovascular device maker today.
The St. Paul, Minnesota-based company said about 91.1 percent of AGA’s outstanding stock was tendered as part of its buyout of the company, and another 6.7 percent of AGA stock was tendered by notices of guaranteed delivery.
St. Jude said it calculated the exchange rate by dividing $20.80 by $38.54, which is the volume weighted average of the daily closing prices of STJ stock for the 10 trading days that ending Nov. 15, the second trading day prior to its planned expiration date for the exchange offer. The company said it conducted the deal with a so-called “a short-form merger” through its subsidiary Asteroid Subsidiary Corp.
Health Benefit Consultants, Share Your Expert Insights in Our Survey
MassDevice Staff Website The Massachusetts Medical Devices Journal is the online journal of the medical devices industry in the Commonwealth and New England, providing day-to-day coverage of the devices that save lives, the people behind them, and the burgeoning trends and developments within the industry.
The acquisition agreement stipulated that each AGAM shareholder receive $10.40 in cash and $10.40 worth of STJ stock. The agreement was based on AGAM’s average closing price during the 10 trading days ending two days before St. Jude began buying up AGAM shares on Oct. 20, according to St. Jude’s announcement of the merger.
Plymouth, Minnesota-based AGA develops devices used to repair structural heart defects and treat vascular diseases. The company will be subsumed by St. Jude’s cardiovascular unit, which makes vascular closure and heart valve products.
STJ shares closed at $39.31, up 2.1 percent for the day. AGAM shares closed at $21.20, up 2.2 percent.
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
The Massachusetts Medical Devices Journal is the online journal of the medical devices industry in the Commonwealth and New England, providing day-to-day coverage of the devices that save lives, the people behind them, and the burgeoning trends and developments within the industry.
